Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
DiarrheaClostridium Difficile
Interventions
DRUG

Tigecycline

: Standard treatment doses of oral antibiotics (vancomycin or metronidazole) for CDAD along with IV tigecycline (100 milligram loading dose followed by 50 milligrams every 12 hours) will be given to patients during their hospitalization (usually 7-14 days). Patients well enough to go home will receive only oral therapy.

Trial Locations (2)

48824

Michigan State University, East Lansing

48912

Sparrow Hosptial, Lansing

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Gary E. Stein, Pharm.D.

OTHER

NCT01401023 - Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD) | Biotech Hunter | Biotech Hunter